天臣国际医疗科技股份有限公司 募集资金存放与使用情况专项报告的 鉴证报告 苏公 W[2025]E1229 号 目 录 1、募集资金存放与实际使用情况专项报告的鉴证报告………….. 1 2、关于 2024 年度募集资金年度存放与实际使用情况专项报告….3 3、事务所营业执照复印件 4、签字注册会计师资质证明复印件 公证天业会计师事务所（特殊普通合伙） Gongzheng Tianye Certified Public Accountants, SGP 中国．江苏．无锡 Wuxi．Jiangsu．China 总机：86（510）68798988 Tel：86（510）68798988 传真：86（510）68567788 Fax：86（510）68567788 电子信箱：mail@gztycpa.cn E-mail：mail@gztycpa.cn 募集资金存放与使用情况鉴证报告 苏公W[2025]E1229号 天臣国际医疗科技股份有限公司全体股东： 我们接受委托，对后附的天臣国际医疗科技股份有限公司（以下简称"天 臣医疗"）2024年度《募集资金存放与实际使用情况的专项报告》（以下简称"募 集资金专项报告"）进行 ...

天臣国际医疗科技股份有限公司 内部控制审计报告 苏公 W[2025]E1227 号 目 录 | 1、内部控制审计报告 | ………………………………………1 | | --- | --- | | 2、内部控制评价报告 | ………………………………………3 | | 3、事务所营业执照及资质复印件 | | | 4、签字注册会计师资质证明复印件 | | 公证天业会计师事务所（特殊普通合伙） Gongzheng Tianye Certified Public Accountants, SGP | 中国．江苏．无锡 | Wuxi．Jiangsu．China | | --- | --- | | 总机：86（510）68798988 | Tel：86（510）68798988 | | 传真：86（510）68567788 | Fax：86（510）68567788 | | 电子信箱：mail@gztycpa.cn | E-mail：mail@gztycpa.cn | 内部控制审计报告 苏公 W[2025]E1227 号 天臣国际医疗科技股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我 ...

对会计师事务所履行监督职责情况的报告 天臣国际医疗科技股份有限公司（以下简称"公司"）董事会审计委员会根据《中 华人民共和国公司法》《中华人民共和国证券法》《上市公司治理准则》和《国有企 业、上市公司选聘会计师事务所管理办法》等法律法规、规范性文件以及《天臣国际 医疗科技股份有限公司章程》（以下简称"《公司章程》"）和《天臣国际医疗科技股 份有限公司董事会审计委员会工作细则》（以下简称"《董事会审计委员会工作细则》"） 的有关规定，充分发挥监督审查作用，恪尽职守、尽职尽责履行相关职责。现将 2024 年度对会计师事务所履行监督职责的情况汇报如下： 天臣国际医疗科技股份有限公司审计委员会 一、2024 年年审会计师事务所基本情况 （一）会计师事务所基本情况 公证天业会计师事务所（特殊普通合伙）（以下简称"公证天业"）创立于 1982 年，是全国首批经批准具有从事证券、期货相关业务资格及金融业务审计资格的会计 师事务所之一。2013 年 9 月 18 日，转制为特殊普通合伙企业。注册地址为无锡市太 湖新城嘉业财富中心 5-1001 室，首席合伙人为张彩斌。 截至 2024 年 12 月 31 日，公证天业合伙人数 ...

证券代码：688013 证券简称：天臣医疗 公告编号：2025-029 天臣国际医疗科技股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2024年年度股东大会 召开日期时间：2025 年 5 月 20 日 14 点 30 分 召开地点：苏州工业园区东平街 278 号会议室 （五） 网络投票的系统、起止日期和投票时间。 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 东大会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互 联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 （六） 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者的投 票，应按照《上海证券交易所科创板 ...

第二届监事会第十八次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 天臣国际医疗科技股份有限公司（以下简称"公司"）第二届监事会第十八次 会议（以下简称"本次会议"）于 2025 年 4 月 25 日以现场结合通讯的方式召开。 会议通知已于 2025 年 4 月 15 日发送至全体监事。本次会议由监事会主席沈捷尔 女士召集并主持，应出席会议监事 3 人，实际出席会议监事 3 人。本次会议的召 集、召开和审议程序符合《中华人民共和国公司法》（以下简称"《公司法》"） 和《天臣国际医疗科技股份有限公司章程》（以下简称"《公司章程》"）的有 关规定。 二、监事会会议审议情况 会议经与会监事审议并书面表决通过了如下议案： 证券代码：688013 证券简称：天臣医疗 公告编号：2025-024 天臣国际医疗科技股份有限公司 1、审议通过《关于公司<2024 年年度监事会工作报告>的议案》 2024 年，监事会根据《公司法》《公司章程》和《监事会议事规则》等有关 规定，认真开展工作，为保证公司规范 ...

Revenue and Profitability - The company's revenue for Q1 2025 reached ¥65,846,058.15, representing a 9.34% increase compared to ¥60,219,598.04 in the same period last year[4]. - Net profit attributable to shareholders was ¥13,186,665.95, up 16.16% from ¥11,352,005.37 year-on-year[4]. - Basic earnings per share rose to ¥0.17, reflecting a 21.43% increase from ¥0.14 in the previous year[4]. - Net profit for Q1 2025 was ¥13,186,665.95, representing a 15.9% increase from ¥11,352,005.37 in Q1 2024[17]. - The total comprehensive income for Q1 2025 was ¥13,180,346.08, compared to ¥11,402,462.19 in Q1 2024, marking an increase of 15.6%[18]. - The net profit excluding non-recurring gains and losses was ¥11,066,061.56, showing a slight increase of 0.50% from ¥11,011,201.10[4]. Cash Flow - The net cash flow from operating activities increased by 49.33%, amounting to ¥13,130,301.30, driven by higher sales revenue[4][8]. - Cash inflow from operating activities in Q1 2025 totaled ¥74,845,934.24, an increase from ¥70,383,398.75 in Q1 2024[19]. - The net cash flow from operating activities for the first quarter of 2025 was CNY 13,130,301.30, compared to CNY 8,792,670.81 in the same period of 2024, representing a year-over-year increase of approximately 49.5%[20]. - Cash flow from operating activities generated a net cash flow of CNY 5,771,734.01 in Q1 2025, down from CNY 10,914,905.91 in Q1 2024, indicating a decline of about 47.3%[28]. - The total cash outflow from operating activities was CNY 59,891,491.33 in Q1 2025, slightly up from CNY 59,423,259.89 in Q1 2024, indicating a marginal increase of 0.8%[28]. Assets and Liabilities - Total assets at the end of the reporting period were ¥658,930,471.24, a 3.40% increase from ¥637,240,337.63 at the end of the previous year[5]. - The company's current assets totaled RMB 438,095,371.63, slightly down from RMB 445,660,797.33 in the previous period[13]. - The company's total liabilities rose to RMB 87,277,308.40 from RMB 55,814,172.44, marking an increase of approximately 56.3%[14]. - The total liabilities increased to CNY 83,651,915.61 as of March 31, 2025, compared to CNY 53,138,321.15 at the end of 2024, showing a significant rise of approximately 57.2%[23]. - The total assets as of March 31, 2025, amounted to CNY 671,335,004.80, an increase from CNY 651,747,172.25 at the end of 2024, indicating a growth of approximately 3.5%[23]. Research and Development - Research and development expenses totaled ¥8,771,673.72, which is a 23.57% increase from ¥7,098,705.62, accounting for 13.32% of revenue[4][5]. - Research and development expenses for Q1 2025 were ¥8,771,673.72, up 23.6% from ¥7,098,705.62 in Q1 2024[16]. Financial Performance - The weighted average return on equity improved to 2.38%, an increase of 0.43 percentage points from 1.95%[4]. - Financial expenses for Q1 2025 showed a net income of -¥2,773,015.39, compared to -¥718,092.21 in Q1 2024, indicating a significant increase in financial efficiency[16]. - The gross profit margin for the first quarter of 2025 was approximately 57.3%, compared to 57.3% in the first quarter of 2024, indicating stable profitability[24]. Shareholder Equity - The total equity attributable to shareholders decreased by 1.68% to ¥571,653,162.84 from ¥581,426,165.19[5]. - The equity attributable to shareholders was reported at RMB 406,647,134.90, up from RMB 404,852,237.93, reflecting a modest increase[14]. Inventory and Receivables - Accounts receivable increased significantly to RMB 19,580,975.37 from RMB 12,530,351.22, representing a growth of about 56.2%[12]. - The company reported a decrease in inventory to CNY 32,802,103.60 as of March 31, 2025, down from CNY 25,325,840.31 at the end of 2024, indicating improved inventory management[22].

Financial Performance - The company reported a net profit attributable to shareholders of RMB 51,894,845.59 for the year 2024, with a profit distribution plan proposing a cash dividend of RMB 5.00 per 10 shares, totaling RMB 39,959,266.50, which represents 77.00% of the net profit[10]. - The estimated total cash dividends for 2024, including interim dividends and special dividends, is RMB 119,179,342.50, which exceeds the net profit by 229.66%[10]. - The company achieved operating revenue of CNY 272.37 million in 2024, an increase of 7.38% compared to the previous year[30]. - Net profit attributable to shareholders reached CNY 51.89 million, up 9.69% year-on-year; net profit excluding non-recurring items was CNY 46.74 million, a 24.46% increase[30]. - Basic earnings per share were CNY 0.65, reflecting an 8.33% growth; diluted earnings per share were CNY 0.64, up 10.34%[31]. - Total assets increased by 1.70% compared to the beginning of the reporting period, while net assets attributable to shareholders rose by 1.73%[31]. - The company reported a net cash flow from operating activities of CNY 53.41 million, down 35.61% from the previous year[28]. - The company reported a disposal loss of non-current assets amounting to 10.52 million RMB in 2024, compared to a gain of 0.66 million RMB in 2023[35]. - The company’s total non-recurring gains and losses amounted to 51.54 million RMB in 2024, down from 97.57 million RMB in 2023[36]. Dividend Distribution - The total number of shares eligible for dividend distribution is 79,918,533, after excluding 1,237,067 shares held in the repurchase account[10]. - The company plans to maintain its dividend distribution strategy despite potential fluctuations in share capital due to repurchases[11]. - The proposed cash dividend for the first half of 2024 is RMB 5.00 per 10 shares, totaling RMB 39,632,429, which exceeds the net profit attributable to shareholders by 137.37%[197]. - The special cash dividend for 2024 is also set at RMB 5.00 per 10 shares, amounting to RMB 39,587,647, which is 92.60% of the net profit attributable to shareholders for the first three quarters of 2024[197]. - The company plans to distribute a cash dividend of RMB 5.00 per 10 shares to all shareholders, totaling RMB 39,959,266.50, which represents 77.00% of the net profit attributable to shareholders for the fiscal year 2024[199]. - The total expected cash dividend distribution for the fiscal year 2024 is RMB 119,179,342.50, accounting for 229.66% of the net profit attributable to shareholders[199]. - The cash dividend distribution will utilize 98.40% of the company's cumulative undistributed profits as of the end of fiscal year 2024[199]. - The company has revised its cash dividend policy to ensure that the annual profit distribution is at least 20% of the distributable profit for the year or 30% of the average annual distributable profit over the last three years[200]. Research and Development - The company is actively engaged in the research and development of new products, including various types of surgical staplers and cutting devices, which are currently under development[18]. - The company maintained a research and development investment ratio of 13.21% of operating revenue, a slight decrease from the previous year[29]. - The company invested in R&D, resulting in 52 new patent applications and 138 new authorizations, including 116 for core technology inventions[44]. - The company has established a research and development model centered on clinical insights and rapid iteration, conducting over ten domestic and international surgeon meetings to address clinical needs and enhance product innovation[56][57]. - The company is actively building a "Minimally Invasive Surgery Technology Innovation Alliance" with eight institutions, including Fudan University, to advance research and innovation in high-end medical devices[57]. - The company achieved a total R&D investment of ¥35,991,857.36, representing a 1.90% increase from the previous year[85]. - The proportion of total R&D investment to operating revenue decreased by 0.71 percentage points to 13.21%[85]. - The company applied for 53 new patents this year, bringing the total number of patents to 1,724, with 807 patents granted[83]. Market Expansion and Strategy - The company expanded its market presence, successfully obtaining 39 new overseas product registration certificates, bringing the total to 62 countries and regions covered[43]. - The company is actively expanding its marketing channels by integrating online branding with offline expansion strategies[61]. - The increasing prevalence of chronic non-communicable diseases in China is driving the demand for surgical staplers, with a growing focus on minimally invasive surgical techniques[62]. - The company is responding to national centralized procurement policies to better meet market demands and enhance brand influence through partnerships with hospitals and research institutions[59]. - The company is focused on improving product performance to reduce complications associated with stapler use, such as bleeding and leakage[70]. - The company is enhancing its dealer management system to improve service quality and compliance among distributors[59]. - The company plans to continue focusing on innovation and expanding its market presence in both domestic and international markets[30]. - The company will continue to drive dual domestic and international market development strategies, increasing market penetration and brand awareness to benefit more patients[142]. Corporate Governance - The company held three shareholder meetings in 2024, reviewing 12 proposals to ensure equal rights for all shareholders, especially minority shareholders[154]. - The company held 7 supervisory board meetings during the reporting period, reviewing 23 proposals[157]. - The independent directors actively participated in shareholder meetings and board meetings, ensuring the protection of minority shareholders' rights[156]. - The company has maintained independence from its controlling shareholders, with no instances of fund occupation or guarantees provided to them[158]. - The board committees operated within their defined authority, providing professional opinions for board decisions[157]. - The company disclosed information in compliance with regulations, ensuring transparency and equal access for all shareholders[158]. - The total number of shares held by the chairman and general manager remained unchanged at 20,978,130 and 20,934,000 respectively[165]. - The company implemented a restricted stock incentive plan, resulting in an increase of 81,618 shares for the secretary of the board[165]. Employee Management - The company has implemented a comprehensive talent management system, including performance evaluation and employee benefits, to enhance organizational effectiveness and support strategic goals[50]. - The company has a total of 254 employees, with 251 in the parent company and 3 in major subsidiaries[186]. - The employee composition includes 90 production personnel, 62 sales personnel, 54 technical personnel, 7 financial personnel, and 41 administrative personnel[187]. - The company provides various statutory benefits including pension, medical, unemployment, work injury, maternity insurance, housing fund, and paid leave[188]. - The company emphasizes a fair salary system based on job value assessment to attract and retain talent[188]. - The total hours of outsourced labor amounted to 18,394 hours, with total remuneration paid for outsourcing reaching 518,100 CNY[191]. - The company collaborates with external organizations for employee training, focusing on professional skills, occupational qualities, safety regulations, and corporate culture[189]. Risk Management - The company has detailed risk factors associated with its operations in the report, emphasizing the importance of understanding these risks for investors[7]. - The company faces challenges in cost management due to price reductions following centralized procurement, which may lead to market concentration among leading firms[63]. - The company faces risks related to R&D failures, talent retention, and market competition due to centralized procurement policies[95][98][99]. Production and Quality Control - The company emphasizes quality control, adhering to ISO13485 standards and implementing advanced automated production and testing equipment[92]. - The company is focusing on optimizing its quality management system and enhancing production efficiency through the implementation of a manufacturing execution system (MES)[46]. - The company has achieved full network coverage in its production workshops, integrating smart devices and upgrading existing equipment to enhance automation and digitalization, significantly reducing manual intervention and production costs[47]. - The company was awarded the title of "Suzhou Level Intelligent Workshop - Minimally Invasive Surgical Stapler Intelligent Manufacturing Workshop" during the reporting period, indicating a commitment to enhancing smart manufacturing capabilities[47]. Strategic Partnerships and Acquisitions - The company is exploring potential acquisitions to enhance its market position, with a budget of $100 million allocated for this purpose[168]. - A new strategic partnership was announced, expected to generate an additional $20 million in revenue over the next year[168].

证券代码：688013 证券简称：天臣医疗 公告编号：2025-023 天臣国际医疗科技股份有限公司 第二届董事会第二十五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 天臣国际医疗科技股份有限公司（以下简称"公司"）第二届董事会第二十五 次会议于2025年4月25日以现场结合通讯的方式召开。会议通知已于2025年4月15 日通过书面及电话等方式送达全体董事。本次会议由董事长陈望宇先生召集并主 持，应出席会议董事7名，实际出席会议董事7名，本次会议的召集、召开及审议 程序符合《中华人民共和国公司法》及《天臣国际医疗科技股份有限公司章程》 （以下简称"《公司章程》"）的相关规定。 二、董事会会议审议情况 会议经与会董事审议并书面表决通过了如下议案： 1、审议通过《关于公司<2024年年度总经理工作报告>的议案》 经审议，董事会认为：2024年总经理带领公司员工，协调各个部门展开工作， 在公司持续运营等方面继续发挥专业作用，维护公司与全体股东的合法权益，促 进公司稳健经营和规范运作。因此 ...

证券代码：688013 证券简称：天臣医疗 公告编号：2025-025 天臣国际医疗科技股份有限公司 关于 2024 年度利润分配方案及 2025 年中期分红规划的公 告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 每股分配比例：每10股派发现金红利人民币5.00元（含税），不送红股，不以 资本公积金转增股本。 本次利润分配以实施权益分派股权登记日登记的总股本扣除公司回购专用证 券账户中的回购股份为基数，具体日期将在权益分派实施公告中明确。 在实施权益分派股权登记日前，公司总股本扣除公司回购专用证券账户中的 回购股份发生变动的，公司拟维持每股分配金额不变，相应调整分红总额，并将另行 公告具体调整情况，具体金额以实际派发情况为准。 公司未触及《上海证券交易所科创板股票上市规则（2024年4月修订）》（以 下简称《科创板股票上市规则》）第12.9.1条第一款第（八）项规定的可能被实施其他 风险警示的情形。 本次利润分配方案已经公司第二届董事会第二十五次会议和第二届监事会第 十八次会议审议通过，尚需提交公司2 ...

一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.6500 | 0.6000 | 8.33 | 0.5400 | | 每股净资产（元） | 0 | 7.04 | -100 | 6.26 | | 每股公积金(元) | 4.99 | 5.09 | -1.96 | 4.98 | | 每股未分配利润(元) | 1.30 | 1.21 | 7.44 | 0.92 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 2.72 | 2.54 | 7.09 | 2.32 | | 净利润(亿元) | 0.52 | 0.47 | 10.64 | 0.43 | | 净资产收益率(%) | 9.09 | 8.75 | 3.89 | 8.37 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 5011.55万股，累计占流通股比： 61.76%，较上期变化： -165. ...